Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 mars 2025 04h09 HE | Source: Araris Biotech

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech

March 17th, 2025Taiho Pharmaceutical Co., Ltd.Araris Biotech AG Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech Taiho Pharmaceutical Co., Ltd....
08 janv. 2025 08h00 HE | Source: Araris Biotech

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive an upfront fee and milestone payments...
12 nov. 2024 08h00 HE | Source: Araris Biotech

Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem

First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
24 sept. 2024 08h00 HE | Source: Araris Biotech

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...